Atlas Trials

Efficacy and Safety Study of Ravulizumab IV in Pediatric Participants With NMOSD

Clinical trial NCT05346354 · ACTIVE_NOT_RECRUITING

Trial details

NCT number
NCT05346354
Sponsor
Alexion Pharmaceuticals, Inc.
Status
ACTIVE_NOT_RECRUITING
Phase
Phase 2, Phase 3
Study type
INTERVENTIONAL
Neuromyelitis Optica Spectrum Disorder
Start date
2022-06-23
Primary completion
2026-06-22
Enrollment
12

View on ClinicalTrials.gov

Track trials programmatically

Sponsors, conditions and status changes through the Atlas API.